stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Revenue growth
BioCryst Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 60.3%, down 33.8 percentage points from fiscal 2025 (94.1%). Over the past ten years it has ranged from −63.5% (fiscal 2020) to 782.4% (fiscal 2021); the current reading is higher than 73% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 94.1% | 58.10 |
| FY2024 | 36.0% | 13.63 |
| FY2023 | 22.4% | (49.94) |
| FY2022 | 72.3% | (710.07) |
| FY2021 | 782.4% | 845.91 |
| FY2020 | −63.5% | (199.98) |
| FY2019 | 136.5% | 154.45 |
| FY2018 | −18.0% | (13.57) |
| FY2017 | −4.43% | 40.96 |
| FY2016 | −45.4% | (300.01) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 13.1% | (20.50) |
| Jun 2026 | 33.6% | 26.13 |
| Mar 2026 | 7.48% | (201.61) |
| Dec 2025 | 209.1% | 172.95 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ALVO Alvotech compare | 364.3% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 245.2% |
| BCRX BioCryst Pharmaceuticals, Inc. | 60.3% |
| XERS Xeris Biopharma Holdings, Inc. compare | 38.4% |
| ANIP ANI Pharmaceuticals, Inc. compare | 25.9% |
| PBH Prestige Consumer Healthcare Inc. compare | 5.10% |
| PRGO Perrigo Company plc compare | −4.47% |
| TRLV Trulieve Cannabis Corp. compare | −9.09% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement